ReviewCancer discovery2022
Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer.
Review in Cancer discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 38 citations in OpenAlex.
- Understanding the Burden of Coinfection: COVID-19 in Hospitalized Patients with Diagnosed and Undiagnosed Advanced HIV.Current HIV research · 2026Article
- Analysis of tracheal, bronchial, and lung cancer trends in 204 countries from 1990 to 2021 and the impact of COVID-19.Respiratory research · 2025Article
- The impact of the COVID-19 pandemic on the diagnosis, treatment, and prognosis of ovarian cancer in the United States: a retrospective cohort study based on the SEER database.Discover oncology · 2025Article
- Oral antivirals for COVID-19 among patients with cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Article
- Metformin is a potential therapeutic for COVID-19/LUAD by regulating glucose metabolism.Scientific reports · 2024Article
- Racial and Ethnic Inequities in Cancer Care Continuity During the COVID-19 Pandemic Among Those With SARS-CoV-2.JAMA network open · 2024Article
- Oral antivirals for COVID-19 among patients with cancer.Research square · 2024Article
- Factors influencing in-hospital mortality in cancer patients with COVID-19: A retrospective survival analysis.SAGE open medicine · 2024Article
- Outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and COVID-19.Clinical and experimental medicine · 2023Article
- Impact of the COVID-19 pandemic on cancer patients in western Pennsylvania: rural-urban disparities.Cancer causes & control : CCC · 2023Article
- Review
- Impact of the COVID-19 pandemic on cancer care in Ireland - Perspectives from a COVID-19 and Cancer Working Group.Journal of cancer policy · 2023Review
- Review
- Learning from cancer to address COVID-19.Biologia futura · 2023Review
- Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma.BMC cancer · 2023Article
- Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium.Lancet regional health. Americas · 2023Article
- Impact of the first wave of the COVID-19 pandemic on non-COVID inpatient care in southern Spain.Scientific reports · 2023Article
- Outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and COVID-19.Research square · 2023Article
- Cancer, more than a "COVID-19 co-morbidity".Frontiers in oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 13 institutions in 2 countries.
Funding
Abstract
The ongoing coronavirus disease 2019 (COVID-19) pandemic has left patients with current or past history of cancer facing disparate consequences at every stage of the cancer trajectory. This comprehensive review offers a landscape analysis of the current state of the literature on COVID-19 and cancer, including the immune response to COVID-19, risk factors for severe disease, and impact of anticancer therapies. We also review the latest data on treatment of COVID-19 and vaccination safety and efficacy in patients with cancer, as well as the impact of the pandemic on cancer care, including the urgent need for rapid evidence generation and real-world study designs. SIGNIFICANCE: Patients with cancer have faced severe consequences at every stage of the cancer journey due to the COVID-19 pandemic. This comprehensive review offers a landscape analysis of the current state of the field regarding COVID-19 and cancer. We cover the immune response, risk factors for severe disease, and implications for vaccination in patients with cancer, as well as the impact of the COVID-19 pandemic on cancer care delivery. Overall, this review provides an in-depth summary of the key issues facing patients with cancer during this unprecedented health crisis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.